Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …

Purpose: Until recently the role of germline genetics in prostate cancer care was not well
defined. While important questions remain, we reviewed the current understanding of …

Simple Summary Advances in our understanding of the molecular basis of prostate cancer
have resulted in the discovery of a subset of patients harboring germline variants that places …

New classification systems based on molecular features have been introduced to improve
precision medicine for prostate cancer (PCa). This review covers the increasing risk of PCa …

Recent advances clearly demonstrate the potential clinical relevance of germline genetic
testing and somatic genomic profiling in identifying possible therapeutic and/or clinical trial …

Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

The availability and cost of germline and somatic genetic testing have dramatically improved
over the past two decades, enabling precision medicine approaches in oncology, with …

Objective To review the current status of germline and somatic (tumour) genetic testing for
prostate cancer (PCa), and its relevance for clinical practice. Methods A narrative synthesis …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …